S. Durrant

J. Szer, A. Roberts, S. Durrant, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

E. Giné, M. Czuczman, B. Coiffier, 2009 .

Human Gastrointestinal Neoplasia‐Associated Myofibroblasts Can Develop from Bone Marrow‐Derived Cells Following Allogeneic Stem Cell Transplantation

C. Mullighan, P. Browett, M. Michael, 2009, Stem cells.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, T. Hughes, 2015, Leukemia & lymphoma.

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

P. Browett, A. Schwarer, I. Gathmann, 2003, Leukemia.

In situ hybridization detection of light chain mRNA in routine bone marrow trephines from patients with suspected myeloma

I. Lauder, J. Pringle, S. Durrant, 1989, British journal of haematology.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

I. Kerridge, Angel F. Lopez, H. Ramshaw, 2015, Leukemia & lymphoma.

The use of vidarabine in the treatment of human polyomavirus associated acute haemorrhagic cystitis.

S. Durrant, C. Chapman, A. Flower, 1991, Bone marrow transplantation.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

M. Griesshammer, S. Verstovsek, R. Mesa, 2015, The New England journal of medicine.

Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.

K. Tadokoro, S. Porcelli, Y. Koezuka, 2000, Experimental hematology.

Human invariant Vα24+ natural killer T cells activated by α‐galactosylceramide (KRN7000) have cytotoxic anti‐tumour activity through mechanisms distinct from T cells and natural killer cells

K. Tadokoro, S. Porcelli, Y. Koezuka, 2000, Immunology.

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma

K. Tadokoro, A. Boyd, Y. Koezuka, 2001, British Journal of Cancer.

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

J. Matthews, A. Schwarer, D. Gill, 2001, Leukemia.

Practical management of myelofibrosis with ruxolitinib

P. Marlton, S. Durrant, D. Ritchie, 2015, Internal medicine journal.

Subacute encephalopathy associated with human immunodeficiency virus in haemophilia A.

S. Durrant, J. Hows, A. Rahemtulla, 1986, British medical journal.

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

M. Griesshammer, S. Verstovsek, M. Hino, 2020, The Lancet. Haematology.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with

T. Brümmendorf, H. Kantarjian, R. Ribeiro, 2014 .

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

P. Browett, A. Schwarer, Z. Rudzki, 2004 .

Donor-Derived b2a2-Specific T Cells for Immunotherapy of Patients with Chronic Myeloid Leukemia

S. Durrant, J. Bashford, M. Nieda, 2002, Journal of immunotherapy.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

E. Giné, M. Czuczman, B. Coiffier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.

C. Begley, J. Collins, J. Szer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III efficacy study of interleukin‐3 after autologous bone marrow transplantation in patients with malignant lymphoma

E. Vellenga, B. Kiese, D. Winfield, 1999, British journal of haematology.

A case‐based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

S. Durrant, K. Burbury, A. Bajel, 2017, Internal medicine journal.

Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF.

S. Durrant, R. Bird, C. Hutchins, 1997, Leukemia research.

A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia

J. Butler, S. Durrant, K. Morris, 2013, British journal of haematology.

153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies

D. MacFarlane, S. Durrant, R. Allison, 2002, Nuclear medicine communications.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, Annals of Hematology.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

A. Nagler, C. Chuah, P. Guglielmelli, 2019, Haematologica.

Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

J. P. Martins, G. Hill, S. Durrant, 2016, Bone Marrow Transplantation.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, British journal of haematology.

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

M. Griesshammer, S. Verstovsek, C. Harrison, 2013 .

Multicycle H igh-Dose C hemotherapy a nd Filgrastim-Mobilized P eripheral-Blood P rogenitor C ells in W omen W ith H igh-Risk S tage I I o r I II B reast C ancer: Five-Year F ollow-Up

C. Begley, J. Collins, J. Szer, 1999 .

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Clinical lymphoma, myeloma & leukemia.

Outcomes after major or bidirectional ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor‐type secretor plasma with or without plasma exchange

S. Durrant, G. Kennedy, C. Hutchins, 2012, Transfusion.

Human peripheral blood Vα24+ Vβ11+ NKT cells expand following administration of α‐galactosylceramide‐pulsed dendritic cells

H. Yagita, S. Durrant, T. Juji, 2002 .

Fatal Reactivation of Precore Mutant Hepatitis B Virus Associated with Fibrosing Cholestatic Hepatitis after Bone Marrow Transplantation

S. Durrant, W. Cooksley, C. McIvor, 1994, Annals of Internal Medicine.

A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia

S. Durrant, A. Bosly, D. Gibbs, 1999 .

Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications

M. Davenport, R. Khanna, G. Hill, 2013, PloS one.

Post transplant CMV-specific T-cell immune reconstitution in the absence of global T-cell immunity is associated with a high risk of subsequent virus reactivation

R. Khanna, G. Hill, D. Cromer, 2015, Bone Marrow Transplantation.

Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B

R. Sylvester, P. Moreau, G. Samonis, 2004, Antimicrobial Agents and Chemotherapy.

Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

R. Herrmann, J. Szer, J. Matthews, 1999, British journal of haematology.

Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis

S. Durrant, I. Irving, P. Mollee, 2001, British journal of haematology.

Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.

G. Hill, S. Durrant, S. Olver, 2019, Blood advances.

A Phase 3 Double-Blind Study of the Addition of Tocilizumab versus Placebo to Cyclosporin/Methotrexate GvHD Prophylaxis.

S. Paul, G. Hill, K. Gartlan, 2021, Blood.

Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): A multicenter trial

J. Lipton, D. Vesole, A. Langston, 2006 .

Origin of Langerhans cells in normal skin and chronic GVHD after hematopoietic stem‐cell transplantation

K. Khosrotehrani, G. Hill, S. Durrant, 2014, Experimental dermatology.

Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.

R. Herrmann, J. Szer, A. Schwarer, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2018, Blood.

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2017 .

The clinical relevance of plasma viscosity in Hodgkin's disease.

I. Lauder, S. Durrant, J. Thompson, 2008, Clinical and laboratory haematology.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

Successful remission of chronic, refractory autoimmune thrombocytopenic purpura following non-myeloablative allogeneic stem cell transplantation

S. Durrant, T. Frost, J. Butler, 2003, Bone Marrow Transplantation.

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

N. Cloonan, G. Thomas, G. Boyle, 2014, The Lancet. Oncology.

Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.

J. Szer, A. Roberts, G. Hill, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Potential impact of AUSFTA on Australiaˈs blood supply

S. Durrant, G. Kennedy, J. Cummings, 2007, The Medical journal of Australia.

Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review.

P. Mathieson, J. Newsom-Davis, S. Durrant, 1990, The Quarterly journal of medicine.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Pegylated interferon-2a invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation

G. Hill, S. Durrant, S. Olver, 2019 .

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

J. Szer, J. Matthews, A. Schwarer, 2005, Blood.

The Addition Of Interleukin-6 Inhibition To Standard Gvhd Prophylaxis Prevents Acute Gvhd: Interim Results Of a Phase I/II Clinical Study

G. Hill, S. Durrant, S. Olver, 2013 .

High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival

J. Scholefield, A. Al-Attar, S. Durrant, 2013, British Journal of Cancer.

Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma

R. Herrmann, I. Lewis, P. Marlton, 2006, Leukemia & lymphoma.

All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand

J. Szer, D. Ma, S. Durrant, 2016, Bone Marrow Transplantation.

Survival following Mechanical Ventilation of Recipients of Bone Marrow Transplants and Peripheral Blood Stem Cell Transplants

R. Boots, S. Durrant, T. Morgan, 2002 .

Survival following Mechanical Ventilation of Recipients of Bone Marrow Transplants and Peripheral Blood Stem Cell Transplants

R. Boots, S. Durrant, T. Morgan, 2002, Anaesthesia and intensive care.

Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation associated with improved survival?

S. Durrant, G. Kennedy, C. Curley, 2013, Asia-Pacific journal of clinical oncology.

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

J. Butler, S. Durrant, G. Kennedy, 2010, Bone Marrow Transplantation.

Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria

J. Butler, S. Durrant, G. Kennedy, 2009, Transfusion.

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J. Szer, T. Hughes, S. Durrant, 2004, Internal medicine journal.

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

S. Durrant, I. Lewis, J. Marty, 2003, Bone Marrow Transplantation.

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia

H. Dombret, H. Kantarjian, A. Wei, 2019, Leukemia & lymphoma.

High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation

S. Durrant, N. Weber, G. Kennedy, 2022, Bone Marrow Transplantation.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD

S. Durrant, M. Nakagaki, G. Kennedy, 2011, Bone Marrow Transplantation.

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer, S. Verstovsek, R. Mesa, 2014 .

Single dose per cycle pegfilgrastim successfully supports full dose intensity CHOP-14 in patients over 60 years with non-Hodgkin's lymphoma (NHL) and successfully mobilises peripheral blood progenitor cells (PBPC).

R. Herrmann, I. Lewis, P. Marlton, 2003 .

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

I. Lewis, P. Marlton, A. Roberts, 2008 .

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

P. Greenberg, J. Cortes, I. Lewis, 2014 .

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

I. Kerridge, C. Tiley, S. Harrison, 2020 .

Activity and outcomes of autologous stem cell transplantation in the private sector in Australia

R. Ware, S. Durrant, I. Irving, 2022, Internal medicine journal.

Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular haemodialysis treatment

J. Feehally, J. Walls, S. Durrant, 1991, British journal of haematology.

Sciatic nerve compression following bone marrow harvest

M. Cooper, S. Durrant, I. Irving, 2000, Bone Marrow Transplantation.

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .

Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen

J. Butler, S. Durrant, G. Kennedy, 2005, Leukemia.

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation

M. Horowitz, D. Parenti, F. Foss, 2010, Bone Marrow Transplantation.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.

A. Boyd, H. Yagita, S. Durrant, 2002, Vox sanguinis.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial

J. Szer, A. Boyd, S. Durrant, 2015, Leukemia & lymphoma.